MedTrace Logo

Systemic Bioactivity of Inhaled Nebulized RNS60

NCT02490865 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2015-09-22

No results posted yet for this study

Summary

The study aims to determine the effects of nebulized RNS60 on selected biomarkers in the circulation.

Conditions

  • Systemic Bioactivity of Nebulized RNS60

Interventions

DRUG

RNS60

RNS60, 4 ml dose nebulized twice daily

DRUG

Normal saline

Normal Saline, 4 ml dose nebulized twice daily

Sponsors & Collaborators

  • Revalesio Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490865 on ClinicalTrials.gov